- Home
- NWTN vs INBX Comparison
NWTN vs INBX Comparison
Compare NWTN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWTN
- INBX
- Stock Information
- Founded
- NWTN 2016
- INBX 2010
- Country
- NWTN United Arab Emirates
- INBX United States
- Employees
- NWTN N/A
- INBX N/A
- Industry
- NWTN Auto Manufacturing
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- NWTN Consumer Discretionary
- INBX Health Care
- Exchange
- NWTN Nasdaq
- INBX Nasdaq
- Market Cap
- NWTN 243.3M
- INBX 222.5M
- IPO Year
- NWTN N/A
- INBX 2020
- Fundamental
- Price
- NWTN $1.23
- INBX $13.85
- Analyst Decision
- NWTN
- INBX Hold
- Analyst Count
- NWTN 0
- INBX 1
- Target Price
- NWTN N/A
- INBX N/A
- AVG Volume (30 Days)
- NWTN 1.2M
- INBX 58.0K
- Earning Date
- NWTN 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- NWTN N/A
- INBX N/A
- EPS Growth
- NWTN N/A
- INBX N/A
- EPS
- NWTN N/A
- INBX 119.38
- Revenue
- NWTN $583,000.00
- INBX $1,568,000.00
- Revenue This Year
- NWTN N/A
- INBX N/A
- Revenue Next Year
- NWTN N/A
- INBX N/A
- P/E Ratio
- NWTN N/A
- INBX $0.12
- Revenue Growth
- NWTN N/A
- INBX 19.24
- 52 Week Low
- NWTN $0.53
- INBX $10.80
- 52 Week High
- NWTN $8.74
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- NWTN 57.71
- INBX 30.41
- Support Level
- NWTN $0.99
- INBX $15.97
- Resistance Level
- NWTN $1.77
- INBX $17.41
- Average True Range (ATR)
- NWTN 0.20
- INBX 0.85
- MACD
- NWTN 0.04
- INBX -0.25
- Stochastic Oscillator
- NWTN 45.67
- INBX 0.00
About NWTN NWTN Inc.
NWTN Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.